| 摘要 |
The invention relates to a CIC-7 protein that is presented on the cell surface and/or plasma membrane, characterised in that the interaction between CIC-7 and the endosomal and/or lysosomal sorting machinery, such as one or more adaptor proteins (AP) and/or Golgi-localized, ³-ear containing, Arf-binding adaptor proteins (GGA), is inhibited and/or disrupted, preferably by mutation or deletion of the amino acid sequences of one or more AP and/or GGA recognition motifs. The invention further relates to a cell-based assay system in which a CIC-7 protein is presented on the cell surface and/or plasma membrane of a cell, with which test compounds are screened for activity in modulating proton and/or chloride transport via CIC-7. Such compounds are intended for application in the treatment of osteoporosis. |
